IRIS
Costanzo, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.201
AS - Asia 8.577
EU - Europa 2.588
SA - Sud America 1.690
AF - Africa 353
Continente sconosciuto - Info sul continente non disponibili 304
OC - Oceania 28
AN - Antartide 1
Totale 29.742
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.803
SG - Singapore 5.288
CN - Cina 1.470
BR - Brasile 1.385
VN - Vietnam 818
IT - Italia 611
FI - Finlandia 376
IE - Irlanda 331
DE - Germania 249
HK - Hong Kong 244
NG - Nigeria 225
GB - Regno Unito 217
CA - Canada 213
FR - Francia 197
IN - India 165
NL - Olanda 126
AR - Argentina 112
BD - Bangladesh 101
MX - Messico 88
TR - Turchia 73
SE - Svezia 68
EC - Ecuador 59
RU - Federazione Russa 59
BE - Belgio 55
ES - Italia 55
IQ - Iraq 50
ID - Indonesia 45
UA - Ucraina 44
ZA - Sudafrica 43
PK - Pakistan 42
PL - Polonia 39
JP - Giappone 34
IL - Israele 29
CL - Cile 26
CO - Colombia 26
VE - Venezuela 26
PE - Perù 21
AU - Australia 20
JM - Giamaica 20
JO - Giordania 19
CZ - Repubblica Ceca 18
PH - Filippine 18
SA - Arabia Saudita 18
UZ - Uzbekistan 18
PY - Paraguay 16
RO - Romania 16
GR - Grecia 15
MY - Malesia 15
EG - Egitto 14
KR - Corea 14
TN - Tunisia 14
CR - Costa Rica 13
AE - Emirati Arabi Uniti 12
CH - Svizzera 12
DO - Repubblica Dominicana 12
NP - Nepal 12
A2 - ???statistics.table.value.countryCode.A2??? 11
AL - Albania 11
AZ - Azerbaigian 11
LT - Lituania 11
MA - Marocco 11
DZ - Algeria 10
HU - Ungheria 10
OM - Oman 10
KE - Kenya 9
TH - Thailandia 9
UY - Uruguay 9
AT - Austria 8
ET - Etiopia 8
KZ - Kazakistan 8
RS - Serbia 8
TT - Trinidad e Tobago 8
DK - Danimarca 7
HN - Honduras 7
KG - Kirghizistan 7
NZ - Nuova Zelanda 7
PA - Panama 7
IR - Iran 6
PS - Palestinian Territory 6
PT - Portogallo 6
BG - Bulgaria 5
BO - Bolivia 5
EE - Estonia 5
MD - Moldavia 5
NI - Nicaragua 5
NO - Norvegia 5
SN - Senegal 5
XK - ???statistics.table.value.countryCode.XK??? 5
AG - Antigua e Barbuda 4
AO - Angola 4
BH - Bahrain 4
GT - Guatemala 4
LB - Libano 4
LV - Lettonia 4
LY - Libia 4
PR - Porto Rico 4
SK - Slovacchia (Repubblica Slovacca) 4
TW - Taiwan 4
BA - Bosnia-Erzegovina 3
BN - Brunei Darussalam 3
Totale 29.400
Salva come PNG Salva come JPEG
Città #
Singapore 2.239
Chandler 1.695
Wilmington 1.454
Ashburn 1.191
San Jose 987
The Dalles 730
Shanghai 679
San Mateo 575
Dallas 514
Council Bluffs 469
Ann Arbor 454
Helsinki 373
Boardman 356
Dublin 330
New York 326
Beijing 310
Ho Chi Minh City 300
Princeton 275
Lawrence 263
Leawood 259
Santa Clara 234
Hong Kong 225
Benin City 223
Milan 218
Los Angeles 216
Hanoi 184
Fairfield 147
Paris 138
Woodbridge 134
São Paulo 125
Phoenix 117
Amsterdam 99
London 79
Seattle 76
Toronto 76
Buffalo 74
Rome 69
Chicago 61
San Diego 57
Brussels 52
Atlanta 51
Brooklyn 47
Orem 47
Houston 44
Belo Horizonte 41
Rio de Janeiro 37
Chennai 35
Columbus 35
Falls Church 34
Haiphong 34
Montreal 33
Charlotte 32
San Francisco 31
Da Nang 30
Warsaw 30
Tokyo 29
Kocaeli 28
Queens 28
Falkenstein 27
Norwalk 27
Figino 26
Johannesburg 26
Manchester 26
Philadelphia 26
Las Vegas 25
Miami 25
Cleveland 24
Mexico City 24
Boston 22
Frankfurt am Main 21
North Bergen 21
Munich 19
Quito 19
Curitiba 18
Detroit 18
Guarulhos 18
Amman 17
Campinas 17
Guayaquil 17
Hải Dương 17
Lima 17
Tashkent 17
Dhaka 16
Goiânia 16
Kingston 16
Redmond 16
The Bronx 16
Lahore 15
Moscow 15
Salvador 15
Baghdad 14
Can Tho 14
Istanbul 14
Naples 14
New Delhi 14
Pasadena 14
Brasília 13
Denver 13
Jacksonville 13
Long Beach 13
Totale 17.804
Salva come PNG Salva come JPEG
Nome #
Living with Chronic Spontaneous Urticaria in Italy: A Narrative Medicine Project to Improve the Pathway of Patient Care 339
Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study 303
Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective Experience 212
CD28 costimulation regulates FOXP3 in a RelA/NF-κB-dependent mechanism. 161
y Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis 159
DNA Methylation Signature in Monozygotic Twins Discordant for Psoriatic Disease 140
Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics 138
A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias 134
Brodalumab: a new way to inhibit IL-17 in psoriasis 133
Chronic Hand Eczema (CHE): A Narrative Review 128
IL-21 in the pathogenesis and treatment of skin diseases. 127
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial 127
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16-week multicentre retrospective study 126
Actinic keratosis treated with an immune response modifier: a case report of six patients 124
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study 124
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis) 123
'Living with chronic urticaria': a study through narrative medicine to improve the quality of care 120
A role of p73 in mitotic exit 119
Rosacea-like Acute Reaction After Hyaluronic Acid Dermal Filler 118
Herpes simplex virus disrupts NF-kappa B regulation by blocking its recruitment on the I kappa B alpha promoter and directing the factor on viral genes 118
FGF8, c-Abl and p300 participate in a pathway that controls stability and function of the Delta Np63 alpha protein 117
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis 117
A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever 117
Psoriasis: from pathogenesis to novel therapeutic approaches. 113
Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis 113
A symphony of regulations centered on p63 to control development of ectoderm-derived structures. 113
Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway 113
How to make a skin-tight dress: the p63/claudin-1 connection 112
A feedback regulatory loop between p63 and Dlx3: implications for epidermal differentiation 112
Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. 112
A p38-dependent pathway regulates DNp63 DNA binding to p53 dependent promoters in UV-induced apoptosis of keratinocytes 111
p63-dependent and independent mechanisms of nectin-1 and -4 regulation in the epidermis. 109
A p38-dependent pathway regulates Delta Np63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes 109
Infliximab in psoriasis and psoriatic arthritis. 109
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis) 108
A role for the p63-IKKalpha pathway in the development of ectodermal dysplasias 106
Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling 105
A myogenic differentiation checkpoint activated by genotoxic stress 105
Age and gender influence on HIDRAdisk outcomes in adalimumab-treated hidradenitis suppurativa patients 105
p63 induces key target genes required for epidermal morphogenesis 104
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. 104
Noninferiority of biosimilar MSB110222 to reference adalimumab for chronic plaque psoriasis 104
Specific Infiltrate of Hodgkin Lymphoma at Site of Cellulitis Mimicking Secondary Cutaneous Involvement 104
Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study) 104
Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis 104
Cutaneous and Mucosal Manifestations of Sjögren’s Syndrome 103
Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology. 1997 Oct;113(4):1384-9 102
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 102
p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis 101
Diagnosis and management of moderate to severe adult atopic dermatitis: a Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA) 101
Adalimumab for severe psoriasis and psoriatic arthritis: an open label study in 30 patients previously treated with other biologics 101
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis 99
Programmed cell death in the skin 99
Zosteriform metastasis of occult bronchogenic carcinoma. 99
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 99
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study 99
The p53/p63/p73 family of transcription factors: overlapping and distinct functions. . 2000 May;113 ( Pt 10):1661-70 98
CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappa B subunits on IL-8 and Bcl-xL gene promotors 97
Efalizumab 97
Living Matter Observations with a Novel Hyperspectral Supercontinuum Confocal Microscope for VIS to Near-IR Reflectance Spectroscopy 96
Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome. 96
Topical use of valproic acid for the prevention or treatment of skin disorders 96
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19 96
Treatment of psoriasis and psoriatic arthritis. 95
Disease-related and drug-induced skin manifestations in inflammatory bowel disease 95
Role of the HLA-C(star)06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients 95
Patient-relevant needs and treatment goals in nail psoriasis. 95
The tumor suppressor activity of IKK alpha in stratified epithelia is exerted in part via the TGF-beta anti proliferative pathway 95
High-dose intravenous immunoglobulin for severe drug reactions: Efficacy in toxic epidermal necrolysis 95
No metagenomic evidence of tumorigenic viruses in cancers from a selected cohort of immunosuppressed subjects 94
Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study 94
IKKalpha downregulation in psoriasis: New insights in the pathway regulating keratinocyte proliferation 93
c-E10 is a caspase-recruiting domain-containing protein that interacts with components of death receptors signaling pathway and activates nuclear factor-kappaB 93
HLA‐C*06 and psoriasis: susceptibility, phenotype, course and response to treatment 93
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 93
Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. 93
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab 92
Prevalence and genomic variability of transfusion transmitted virus in Italian cryptogenic chronic liver disease and healthy blood donors. 92
Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta 92
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population 92
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study 91
Two new p73 splice variants, gamma and delta, with different transcriptional activity 91
Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target. 91
p73 is regulated by phosphorylation at the G2/M transition 91
HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naive patients 91
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients 91
The p73 gene is an anti-tumoral target of the RAR beta/gamma-selective retinoid tazarotene 90
DNp73 alpha protects myogenic cells from apoptosis. 90
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope 90
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 90
Frontal Fibrosing Alopecia Associated With Oral Erosive Lichen Planus: Two Locations, One Disease 89
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 89
Delta Np63 knockdown mice: a mouse model for AEC syndrome 89
Keratosis punctata palmoplantaris and malignancies: Case report 89
DLX5, FGF8 and the Pin1 isomerase control ΔNp63α protein stability during limb development: a regulatory loop at the basis of the SHFM and EEC congenital malformations. 89
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 89
Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. 89
TRIM8 and p53: making the right decision. 88
Role of p63 in keratinocyte differentiation and proliferation 88
Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension. 88
Totale 10.968
Salva come PNG Salva come JPEG
Categoria #
all - tutte 190.516
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 190.516
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.392 0 0 0 323 21 38 57 195 143 111 413 91
2022/20234.235 595 166 374 543 399 390 5 353 790 319 242 59
2023/20242.627 158 237 592 68 54 222 174 416 44 54 211 397
2024/20254.124 107 80 45 64 66 427 260 396 571 981 533 594
2025/202610.645 1.598 688 662 999 392 426 3.116 519 549 591 407 698
2026/20273.964 727 904 1.848 485 0 0 0 0 0 0 0 0
Totale 29.742